SGCG and neoplasm: Riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana, preferentially binds to the branched bi- and triantennary N-glycan structures NA2 and NA329, which may help riproximin to recognize the glycans in cancer cells, resulting in tumor-specific cytotoxicity.